The Week In... Pharma (09-13/09)
  • Posted on: 13/09/2019
  • Category: Industry

The Week In... Pharma (09-13/09)

Novo Nordisk is to launch a cut-price version of its insulin drug, a Slovakian biotech sees positive developments in its Alzheimer’s drug, the NHS looks at making statins available for pharmacists, and AZ’s cancer drug Imfinzi shows significant survival benefits. 

Interested in Star’s innovative outsourcing and resourcing solutions? 

Contact Operations Director, Mark Ward, on 07872 105 540 or email mark.ward@starmedical.co.uk. 

On the hunt for a new role, or just curious? 

Visit our candidate page, submit your CV to candidates@starmedical.co.uk, or give our offices a ring! 

Dependence on prescription medicines linked to deprivation

PHE has published the first-ever evidence review of dependence and withdrawal problems associated with 5 commonly prescribed classes of medicines in England.

Slovakian biotech firm signals tentative Alzheimer's drug hope

An Alzheimer’s vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, a rare step forward in the fight against the brain-wasting disease.

Novo follows Sanofi, Lilly with insulin price cut in US

Novo Nordisk has said it will launch a cut-price version of its insulin drug NovoLog, in the face of criticism over the price of insulin in the US.

NHS to review making statins available for pharmacists

The NHS has announced plans to review making statins available direct from pharmacists, as part of Long Term Plan.

Imfinzi shows survival benefit in aggressive lung cancer

AstraZeneca’s Imfinzi has become the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer (SCLC).

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.